


Author's Accepted Manuscript

Rheumatologic symptoms in oncologic patients on PD-1 inhibitors

Wilson F. Kuswanto, Lindsey A. MacFarlane, Lydia Gedmintas, Alexandra Mulloy, Toni K. Choueiri, Bonnie Bermas



PII: S0049-0172(17)30502-4

DOI: <http://dx.doi.org/10.1016/j.semarthrit.2017.10.018>

Reference: YSARH51264

To appear in: *Seminars in Arthritis and Rheumatism*

Cite this article as: Wilson F. Kuswanto, Lindsey A. MacFarlane, Lydia Gedmintas, Alexandra Mulloy, Toni K. Choueiri and Bonnie Bermas, Rheumatologic symptoms in oncologic patients on PD-1 inhibitors, *Seminars in Arthritis and Rheumatism*, <http://dx.doi.org/10.1016/j.semarthrit.2017.10.018>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Rheumatologic symptoms in oncologic patients on PD-1 inhibitors

Wilson F. Kuswanto M.D. PhD¹, Lindsey A. MacFarlane M.D. M.P.H.², Lydia Gedmintas M.D. M.P.H.², Alexandra Mulloy N.P.³, Toni K. Choueiri M.D.^{1,3}, Bonnie Bermas M.D.²
1. Harvard Medical School, Boston, MA. 2. Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA. 3. Dana Farber Cancer Institute, Boston, MA.

Corresponding author: Lindsey A. MacFarlane M.D. M.P.H.

Division of Rheumatology, Brigham and Women's Hospital

60 Fenwood Road, Boston, MA 02115

Telephone: 617-732-5325. Fax: 617-264-6357.

This work did not receive financial support or other benefits.

Dr. Bermas receives royalties from Up-to-Date and has consulted for UCB

Dr. Choueiri has consulted for AstraZeneca, BMS, Exelixis, Genentech, GSK, Merck, Novartis, Peloton, Pfizer, Roche, Tracon, and Eisai.

The remainder of the authors have no disclosures to report.

Abstract

Objective: Immune check-point inhibitors are effective cancer therapies that have been associated with immune related adverse events (irAEs). Recent reports of irAEs describe symptoms resembling classic rheumatologic syndromes, most notably associated with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor blockade. There are limited reports of rheumatologic disease associated with programmed cell death protein-1 (PD-1) inhibitors. Here, we describe a case series of four patients presenting to the Brigham and Women's Hospital

Download English Version:

<https://daneshyari.com/en/article/8623773>

Download Persian Version:

<https://daneshyari.com/article/8623773>

[Daneshyari.com](https://daneshyari.com)